Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PRP shots may ease nerve pain from chemo

NCT ID NCT05348408

Symptom relief Sponsor: South Egypt Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether injecting platelet-rich plasma (PRP) near nerves can reduce pain and nerve damage caused by chemotherapy. 62 cancer patients with persistent nerve pain received PRP injections guided by ultrasound. Researchers measured pain levels and nerve function to see if the treatment helped.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
platelet-rich plasma (PRP)
What this could lead to
If it works, this could provide a new way to reduce nerve pain and improve quality of life for cancer patients suffering from chemotherapy side effects.
What could go wrong
This is a small, early-phase trial with only 62 participants, so results may not apply to everyone. The treatment involves injections, which carry risks like infection or discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

62 people

The number who actually took part.

Started

Apr 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * cancer patients with peripheral neuropathy confirmed by clinical evaluation and nerve conduction study despite of medical treatment Exclusion Criteria: patients with: * Foot ulcers and / or amputation. * Peripheral vascular disease. * Uncontrolled diabetes * Vertebral pathologies. * Connective tissue diseases. * Thyriod disorders, significant renal or hepatic dysfunction. * Platelet dysfunction syndrome, critical thrombocytopenia. * Septicemia and local infection at the site of the procedure. * Systemic corticosteriod adminstiration or local injection at the suspected treatment site within the last month. * Recent fever or illness. * Hemoglobin level less than 10 g/dl, platelet count less than 105-109/L.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced peripheral neuropathy

Contacts and locations

Locations

  • Pain clinic and intervention unit at South Egypt Cancer Institute, Assuit University

    Asyut, Egypt, 71514, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.